UK government rethinks plans to buy AZ antibody doses – reportThe UK government has got cold feet over plans to buy a million doses of AstraZeneca’s antibody treatment Share XUK government rethinks plans to buy AZ antibody doses – reporthttps://pharmaphorum.com/news/uk-government-rethinks-plans-to-buy-1m-az-antibody-doses-report/
Alvotech files lawsuit challenging AbbVie’s Humira patent thicketBiosimilars firm Alvotech has filed a lawsuit that challenges AbbVie’s legal defences surrounding the inflammatory disease drug Humira Share XAlvotech files lawsuit challenging AbbVie’s Humira patent thickethttps://pharmaphorum.com/news/alvotech-files-lawsuit-challenging-abbvies-humira-patent-thicket/
NICE says ‘no’ to Pfizer’s Vyndaqel for rare heart conditionNICE has rejected regular NHS funding for Pfizer’s Vyndaqel (tafamidis) for a rare heart condition, although it has Share XNICE says ‘no’ to Pfizer’s Vyndaqel for rare heart conditionhttps://pharmaphorum.com/news/nice-says-no-to-pfizers-vyndaqel-for-rare-heart-condition/
FDA authorises Pfizer/BioNTech vaccine for adolescentsThe FDA has authorised Pfizer/BioNTech’s vaccine for 12- to 15 year-olds under emergency rules. In a statement the Share XFDA authorises Pfizer/BioNTech vaccine for adolescentshttps://pharmaphorum.com/news/fda-authorises-pfizer-biontech-vaccine-for-adolescents/
Scotland backs NHS use of Alexion’s Ultomiris for rare disease aHUSNHS patients in Scotland with the rare disease atypical haemolytic uremic syndrome (aHUS) will now be able to Share XScotland backs NHS use of Alexion’s Ultomiris for rare disease aHUShttps://pharmaphorum.com/news/scotland-backs-nhs-use-of-alexions-ultomiris-for-rare-disease-ahus/
EU starts rolling review of GSK’s antibody for COVID-19The EMA has begun a rolling review of a COVID-19 antibody developed by GlaxoSmithKline and Vir BioTech which Share XEU starts rolling review of GSK’s antibody for COVID-19https://pharmaphorum.com/news/eu-starts-rolling-review-of-gsks-antibody-for-covid-19/
Pfizer shares slump as support grows for COVID-19 vaccine patent waiverShares in COVID-19 vaccine manufacturers have taken a hit after the US signalled its support for waiving patents Share XPfizer shares slump as support grows for COVID-19 vaccine patent waiverhttps://pharmaphorum.com/news/pfizer-shares-slump-as-support-grows-for-covid-19-vaccine-patent-waiver/
AstraZeneca’s Farxiga claims first SGLT2 kidney disease OK from FDAAstraZeneca is already seeing sales rocket for its SGLT2 inhibitor Farxiga in heart failure, and is expected to Share XAstraZeneca’s Farxiga claims first SGLT2 kidney disease OK from FDAhttps://pharmaphorum.com/news/astrazenecas-farxiga-gets-first-kidney-disease-ok-from-fda/
Indivior pays $300m to settle Suboxone marketing allegationsIndivior has paid out $300 million to resolve civil claims from US states after it was last year Share XIndivior pays $300m to settle Suboxone marketing allegationshttps://pharmaphorum.com/news/indivior-pays-300m-to-settle-suboxone-marketing-allegations/
